Daybue - HCP resource
Clinical-reference information for healthcare professionals evaluating Daybue for international NPP requests.
Indication (US FDA label)
Rett syndrome. Refer to the manufacturer's US Prescribing Information for the full label.
Modality and mechanism
IGF-1 analog.
Clinical justification for NPP
When Daybue is not locally registered, NPP justification typically includes:
- Confirmed diagnosis meeting the US-label indication.
- Failure, intolerance, or inappropriateness of locally available alternatives.
- Treating-physician attestation of clinical appropriateness.
- Patient consent and understanding of off-label or unregistered status in-country.
Supply provenance
Reserve Meds sources Daybue exclusively from DSCSA-compliant US specialty wholesalers. All product is US-FDA-supply-chain provenance with transaction history documentation.
Cold-chain and logistics
If Daybue requires refrigerated or cryogenic storage, validated cold-chain shipping is standard. Receipt at hospital pharmacy is documented with temperature logs.
Pharmacovigilance
Adverse-event reports for cross-border NPP should be routed to both the local regulator and the US manufacturer. Reserve Meds supports AE-reporting coordination.
Re-supply for chronic therapy
For chronic-therapy indications, renewed prescription and NPP authorisation are coordinated per local regulator cadence.
Questions from treating physicians
- What documentation does the local regulator require?
- What is the typical timeline from prescription to patient receipt?
- What is the patient's out-of-pocket cost?
- How is the drug authenticated on arrival?
- How do I report adverse events?
Contact the clinical team at [email protected].